Metastatic heterogeneity of breast cancer cells is associated with expression of a heterogeneous TGF-{beta}-activating miR-424-503 gene cluster

Transforming growth factor beta (TGF-β) signaling is known to drive metastasis in human cancer. Under physiological conditions, the level of TGF-β activity is tightly controlled by a regulatory network involving multiple negative regulators. At metastasis, however, these inhibitory mechanisms are usually overridden so that oncogenic TGF-β signaling can be overactivated and sustained. To better understand how the TGF-β inhibitors are suppressed in metastatic breast cancer cells, we compared miRNA expression profiles between breast cancers with or without metastasis and found that the miR-424-503 cluster was markedly overexpressed in metastatic breast cancer. Mechanistic studies revealed that miR-424 and miR-503 simultaneously suppressed Smad7 and Smurf2, two key inhibitory factors of TGF-β signaling, leading to enhanced TGF-β signaling and metastatic capability of breast cancer cells. Moreover, antagonizing miR-424-503 in breast cancer cells suppressed metastasis in vivo and increased overall host survival. Interestingly, our study also found that heterogeneous expression of the miR-424-503 cluster contributed to the heterogeneity of TGF-β activity levels in, and metastatic potential of, breast cancer cell subsets. Overall, our findings demonstrate a novel mechanism, mediated by elevated expression of miR-424-503 cluster, underlying TGF-β activation and metastasis of human breast cancer.